Intramuscular Mechanisms of Androgen Deprivation-related Sarcopenia

Inclusion Criteria:

* Histologically, cytologically, or image based documented advanced or metastatic PCa initiating ADT with expected continuous treatment for a minimum of 6 months and willing/able to provide informed consent.
* Willing and able to provide written informed consent prior to screening.

Exclusion Criteria:

* Liver disease (AST or ALT equal or more than 3x normal levels);
* Renal failure (creatinine equal or more than 2.5 mg/dL);
* Untreated thyroid disease, class III-IV CHF, AIDS;
* Other cancer diagnosed within the past five years other than non-melanoma skin cancer;
* Severe COPD requiring use of home O2;
* Chronic, uncontrolled hypertension as judged by the Investigator (i.e., Baseline SBP \>150 mm Hg, DBP \>90 mm Hg) or a SBP \> 150 mm Hg or DBP \> 95 mm Hg at the time of screening or baseline;
* An active, uncontrolled infection or cardiovascular disease including a recent myocardial infarction (MI), cerebrovascular accident (CVA), arrhythmias or unstable angina (\< 6 months);
* Uncontrolled diabetes mellitus (as defined by a HbA1c equal or more than 9%);
* Underlying muscular or neuromuscular disorder or neurologic deficit contributing to sarcopenia;
* Enrolled in a clinical trial involving an investigational product or non-approved use of a drug/device or concurrently enrolled in medical research not scientifically or medically compatible with this study;
* Current use (within one month) of testosterone, high dose steroids (20mg of prednisone/day for more than 1 month), or megestrol treatment for cancer within the previous 3 months;
* Previous treatment with ADT other than oral anti-androgen at initiation of ADT;
* Metal implants in the right limbs (non-MRI compatible metal stents, titanium pins/markers, etc.) or implanted cardiac pacemaker or other implanted non-MRI compatible cardiac device (e.g., stent);
* A history of vascular problems (DVT, etc.)